Ixico beats forecasts on strong demand for brain scan software

Revenue increased year-on-year by 40% to £7.6mln, up from £5.4mln in 2018, while orders at the year-end were £15.9mln


Brain scan specialist IXICO PLC (LON:IXI) will post its first annual underlying profit since it listed after revenues in its latest year surged 40%.

Ixico has developed a suite of sophisticated algorithms that enhance the images from MRI and PET scans to help pharma companies in trials of drugs to treat brain illnesses such as Huntington's, Alzheimer's and Parkinson's.

The company said the performance was better than expected as sales growth had accelerated since the half-year, even though one large trial had finished early.

In the year to September, revenue increased year-on-year by 40% to £7.6mln, up from £5.4mln in 2018, while orders at the year-end were £15.9 million, which takes account of the client early trial cessation reported on 9 August.

Net cash at the year-end was £7.3mln (2018: £7.9mln). 

Giulio Cerroni, IXICO's chief executive, said: "We are very pleased to have again delivered on our client and financial commitments, exceeding full-year guidance, while continuing to invest in the long-term future of the Company.

"2019 has been a pivotal year in the company's transformation into a profitable, scalable business, and we enter 2020 on a strong growth trajectory supported by our order book, highly talented staff and strengthened leadership team."

Quick facts: IXICO PLC

Price: 67 GBX

Market: AIM
Market Cap: £31.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...



IXICO PLC - Proactive One2One Virtual Event

IXICO PLC's Giulio Cerroni speaks to investors at the Proactive One2One Virtual Event. IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

3 weeks, 5 days ago

2 min read